Recursion Pharmaceuticals Inc Cl A (RXRX)

$4.10 -0.08 (-1.91%)
Market Cap 2.18B
Revenue (ttm) 58.84M
Net Income (ttm) -463.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -788.00%
Debt to Equity Ratio 0.01
Volume 23,477,199
Avg Vol 21,913,762
Day's Range N/A - N/A
Shares Out 519.84M
Stochastic %K 11%
Beta 0.95
Analysts Sell
Price Target $7.00

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology
Sector: Healthcare
Phone: 385 269 0203
Fax: 801 821 2872
Address:
41 South Rio Grande Street, Salt Lake City, United States
Samishere
Samishere Feb. 4 at 1:16 AM
$RXRX OUCH!
0 · Reply
billygeek
billygeek Feb. 4 at 1:15 AM
$RXRX This thing has been scraping bottom for so long 👎
0 · Reply
Bernard_Lepson
Bernard_Lepson Feb. 4 at 12:03 AM
$RXRX Subsequent price movement predictions: As long as the price doesn't fall below the support level of $3.95, the resistance level is $4.58 If tomorrow's candlestick opens within the green zone, you can enter the trade directly I will modify the indicators if there are any changes later If you like, you can follow me; you can get daily trading strategies by sending me a private message
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 3 at 10:01 PM
$OPENAI $RXRX $ABCL $SPY
0 · Reply
Zio_Fauss
Zio_Fauss Feb. 3 at 8:42 PM
$RXRX
0 · Reply
MakingMoney20
MakingMoney20 Feb. 3 at 8:22 PM
$RXRX More Bots than Humans in the next 10 -15 years. We Humans still need Recursion! Get it while it's Hot! RXRX $$
1 · Reply
Spartangio
Spartangio Feb. 3 at 8:18 PM
$RXRX Where is the hype ?zero hype in the sector … It will arrive
0 · Reply
Ga0Ga
Ga0Ga Feb. 3 at 8:14 PM
$RXRX https://seekingalpha.com/news/4546502-openai-considers-backing-ai-led-drug-discovery-firms-report
0 · Reply
Ray89c
Ray89c Feb. 3 at 8:12 PM
$ALUR all partnerships slowly building up. Waiting for the big day. FDA approval soon 🤞. As they proving combination therapy with $LLY hope they buyout allur. $PZE $NVO $RXRX
0 · Reply
MakingMoney20
MakingMoney20 Feb. 3 at 8:09 PM
$RXRX This to shall pass! For now, Buying Opportunity! RXRX $$
0 · Reply
Latest News on RXRX
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

Jan 22, 2026, 2:54 PM EST - 12 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 5:46 PM EST - 21 days ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:59 AM EST - 4 weeks ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

3 Small AI Plays to Buy for 2026

Dec 26, 2025, 1:28 PM EST - 5 weeks ago

3 Small AI Plays to Buy for 2026

ANET INOD

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

Dec 18, 2025, 11:38 AM EST - 6 weeks ago

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

What's Happening With RXRX Stock?

Dec 18, 2025, 11:05 AM EST - 6 weeks ago

What's Happening With RXRX Stock?

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Dec 8, 2025, 4:37 PM EST - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:32 AM EST - 2 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 8, 2025, 7:30 AM EST - 2 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Dec 5, 2025, 8:19 AM EST - 2 months ago

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Dec 1, 2025, 8:30 AM EST - 2 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 21, 2025, 7:43 PM EST - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Nov 18, 2025, 10:14 AM EST - 2 months ago

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:11 PM EST - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:30 AM EST - 3 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Nov 5, 2025, 6:28 AM EST - 3 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Recursion to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 3 months ago

Recursion to Participate in Upcoming Investor Conferences

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Oct 28, 2025, 8:00 AM EDT - 3 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

Oct 22, 2025, 1:42 PM EDT - 3 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS IBRX PLUG RKT

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Oct 8, 2025, 2:51 PM EDT - 4 months ago

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 8:03 PM EDT - 5 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 6:51 PM EDT - 5 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 2:44 PM EDT - 6 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 6:30 AM EDT - 6 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 29, 2025, 8:00 AM EDT - 6 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

Jul 25, 2025, 1:53 PM EDT - 6 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Top 2 Health Care Stocks You May Want To Dump This Quarter

Jul 22, 2025, 7:02 AM EDT - 7 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 10, 2025, 6:14 AM EDT - 8 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Jun 6, 2025, 10:00 AM EDT - 8 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 1:37 PM EDT - 9 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 6:00 AM EDT - 9 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 5, 2025, 4:02 AM EDT - 9 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

May 4, 2025, 12:45 PM EDT - 9 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 28, 2025, 8:27 AM EDT - 10 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 22, 2025, 8:34 PM EDT - 10 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 16, 2025, 8:30 AM EDT - 10 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 9, 2025, 8:00 AM EDT - 10 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Recursion to Participate in Upcoming Investor Conference

Apr 1, 2025, 8:00 AM EDT - 11 months ago

Recursion to Participate in Upcoming Investor Conference

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Mar 3, 2025, 11:19 AM EST - 1 year ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 1:16 PM EST - 1 year ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Altitude Lab Startups Raise $154M in Capital

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 13, 2025, 6:05 PM EST - 1 year ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Feb 5, 2025, 5:24 PM EST - 1 year ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 1 year ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Dec 20, 2024, 4:05 PM EST - 1 year ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Dec 12, 2024, 6:07 AM EST - 1 year ago

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Dec 9, 2024, 6:00 PM EST - 1 year ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Samishere
Samishere Feb. 4 at 1:16 AM
$RXRX OUCH!
0 · Reply
billygeek
billygeek Feb. 4 at 1:15 AM
$RXRX This thing has been scraping bottom for so long 👎
0 · Reply
Bernard_Lepson
Bernard_Lepson Feb. 4 at 12:03 AM
$RXRX Subsequent price movement predictions: As long as the price doesn't fall below the support level of $3.95, the resistance level is $4.58 If tomorrow's candlestick opens within the green zone, you can enter the trade directly I will modify the indicators if there are any changes later If you like, you can follow me; you can get daily trading strategies by sending me a private message
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 3 at 10:01 PM
$OPENAI $RXRX $ABCL $SPY
0 · Reply
Zio_Fauss
Zio_Fauss Feb. 3 at 8:42 PM
$RXRX
0 · Reply
MakingMoney20
MakingMoney20 Feb. 3 at 8:22 PM
$RXRX More Bots than Humans in the next 10 -15 years. We Humans still need Recursion! Get it while it's Hot! RXRX $$
1 · Reply
Spartangio
Spartangio Feb. 3 at 8:18 PM
$RXRX Where is the hype ?zero hype in the sector … It will arrive
0 · Reply
Ga0Ga
Ga0Ga Feb. 3 at 8:14 PM
$RXRX https://seekingalpha.com/news/4546502-openai-considers-backing-ai-led-drug-discovery-firms-report
0 · Reply
Ray89c
Ray89c Feb. 3 at 8:12 PM
$ALUR all partnerships slowly building up. Waiting for the big day. FDA approval soon 🤞. As they proving combination therapy with $LLY hope they buyout allur. $PZE $NVO $RXRX
0 · Reply
MakingMoney20
MakingMoney20 Feb. 3 at 8:09 PM
$RXRX This to shall pass! For now, Buying Opportunity! RXRX $$
0 · Reply
Ga0Ga
Ga0Ga Feb. 3 at 8:05 PM
$RXRX https://www.ad-hoc-news.de/boerse/news/ueberblick/recursion-pharmaceuticals-approaches-a-pivotal-financial-and-clinical/68548328#google_vignette
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Feb. 3 at 7:44 PM
Result summaries are very crucial to keep track of how the strategy is going. Here's track record showing the results for Small + Mid cap stocks. Will next trade $RXRX + $ADPT and more like I did for small + mid cap stocks when H% is low. Do you see why I only buy when H% is low? All include timestamps + buy fills for everything. The result speaks for itself.
0 · Reply
Zio_Fauss
Zio_Fauss Feb. 3 at 7:04 PM
$RXRX Pure speculation, nothing more. It’s dropping because the indices are dragging it down. At this point we’re basically on the floor. Now it’s up to the institutional investors to show what they actually intend to do, and whether they truly believe in this.
0 · Reply
WolfofKarachi
WolfofKarachi Feb. 3 at 7:03 PM
$RXRX Total carnage
0 · Reply
Zio_Fauss
Zio_Fauss Feb. 3 at 6:51 PM
$RXRX critical moment….
0 · Reply
Lh2838
Lh2838 Feb. 3 at 6:09 PM
$RXRX say when
0 · Reply
joeypignuts
joeypignuts Feb. 3 at 5:13 PM
$RXRX unbelievable.
0 · Reply
Spartangio
Spartangio Feb. 3 at 4:46 PM
$RXRX Tech selloff not safe from it Anyway from today ARK now own 37 mln shares +15%
1 · Reply
Brodman
Brodman Feb. 3 at 4:20 PM
$RXRX All HYPE...This will be $2 after earnings. No way they make it long term. The big guys will be out of this soon. They aren't going to stick around long and lose a ton...no way.
0 · Reply
Floridaorange
Floridaorange Feb. 3 at 3:06 PM
$IBRX $RXRX https://www.youtube.com/watch?v=jY7AUFpnQJQ
0 · Reply
Ga0Ga
Ga0Ga Feb. 3 at 2:53 PM
$RXRX 🙏🏻
0 · Reply
Ryan071236
Ryan071236 Feb. 3 at 2:31 PM
$RXRX youve got 2 years until this plays out if ever. this will go to $2 after they dulute the shares end of 2027. after that it will depend on drugs and potential. dead money until then, or dead money flat out.
0 · Reply